Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)

• Status: Completed
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer

Criteria

Inclusion Criteria:

• Diagnosis of atopic dermatitis according to Hanifin and Rajka criteria

• Body surface area affected by atopic dermatitis at or less than 15% at start of treatment

Exclusion Criteria:

• Pregnancy and breast-feeding

• Conditions that may pose a threat to the patient or effect the outcome of the study

• Wide-spread atopic dermatitis (AD) requiring systemic treatment

• Immuno-compromized conditions

• At least 2 weeks after local AD treatment and treatment with systemic antibiotics

• At least 1 month after systemic AD treatment